CMS to Reimburse for Genetic Testing in Iverson's Warfarin PGx Study; Genmark to Provide Platform

The CMS approval "is for a clinical study under 'coverage with evidence development' and will cover pharmacogenetic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness," Iverson Genetics said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.